Blood News and Research

RSS

Early urinary protein content test during pregnancy predicts later pre-eclampsia

Research led by the University of Leicester and University Hospitals of Leicester NHS Trust has provided a new advance in predicting a potentially serious pregnancy complication.

24 Nov 2010

FTC/TDF tablet reduces HIV infection among high-risk individuals: iPrEx study

In a finding with the potential to fundamentally change strategies to slow the global HIV epidemic, a new study called iPrEx shows that individuals at high risk for HIV infection who took a single daily tablet containing two widely used HIV medications, emtricitabine and tenofovir (FTC/TDF), experienced an average of 43.8% fewer HIV infections than those who received a placebo pill. New England Journal of Medicine, is the first evidence that this new HIV prevention method, called pre-exposure prophylaxis or PrEP, reduces HIV infection risk in people.

24 Nov 2010

SIRS-Lab, Pfizer collaborate to improve patients’ outcome with sepsis

SIRS-Lab GmbH, a molecular diagnostics company based in Jena, Germany, and Pfizer Pharma GmbH, headquartered in Berlin, have announced a collaboration in the field of sepsis.

24 Nov 2010

Novel sharps disposal device reduces container-associated sharps injuries by 81%

A safety enhanced disposal device could prevent more than 19,000 accidental needlesticks and other "sharps" injuries to healthcare workers, suggests a study published in the current issue of the American Journal of Infection Control.

24 Nov 2010

Important queries about PrEP, iPrEx trial for HIV infection

The results of the iPrEx PrEP effectiveness trial of once-daily TDF/FTC (brand name Truvada) in gay men, transgender women and other men who have sex with men are a landmark in HIV prevention research.

24 Nov 2010

HIV treatment drugs also help prevent HIV infection in high-risk men: Study

In a significant advance for HIV prevention research, a clinical trial confirms that the same drugs used for treating HIV can also help prevent HIV infection in the first place.

24 Nov 2010

Los Angeles philanthropist foundation model to commercialize research at Ben-Gurion University

A Los Angeles philanthropist has created an innovative foundation model that will provide up to $1.2 million to help fund and commercialize research at Ben-Gurion University of the Negev in Beer-Sheva, Israel.

24 Nov 2010

Plant-derived bioscavenger protects against pesticide and nerve agent organophosphate poisoning

The brain is forever chattering to itself, via electrical impulses sent along its hard-wired neuronal "Ethernet." These e-messages are translated into chemical transmissions, allowing communication across the narrow cleft separating one neuron from another or between neurons and their target cells. Of the many kinds of molecules involved in this lively chemical symposium, acetylcholine is among the most critical, performing a host of functions in the central and peripheral nervous system.

24 Nov 2010

Testing less frequently not a good way to economize for people living with diabetes

The American economy is struggling— and people living with diabetes are feeling the brunt of the rising prices of medical supplies and doctor visit co-pays. In a recent poll by dLife.com, more than 400 people living with diabetes revealed they struggle when it comes to paying for diabetic supplies.

24 Nov 2010

NIH expands genetic and clinical research database to provide access to digital study images

The National Institutes of Health has expanded a genetic and clinical research database to give researchers access to the first digital study images.

24 Nov 2010

Software that simulates blood flow receives George Bell Prize for world's fastest supercomputing application

Researchers at New York University's Courant Institute of Mathematical Sciences have received the George Bell Prize, given to the world's fastest supercomputing application, for creating software that simulates blood flow. The award, which includes a cash prize of $10,000 and is given by the Association for Computing Machinery (ACM), is shared with researchers at Georgia Tech and Oak Ridge National Laboratory (ORNL).

24 Nov 2010

Centenary Institute launches new BD LSR-9 Flow Cytometer with nine lasers for studies of rare cells

A world-first research system to be launched today at the Centenary Institute will give medical researchers in Australia a new weapon in the fight against cancer and other life-threatening diseases. The new BD LSR-9 Flow Cytometer with its nine lasers will be the first user-operated flow cytometer with unprecedented ability to detect and analyse rare cells.

24 Nov 2010

Hepcidin hormone may be potential therapeutic tool for anemic blood disorders

A hormone made by the body may be a potential therapeutic tool for the treatment of two anemic blood disorders beta-thalassemia and hemochromatosis. The new research was led by scientists at Weill Cornell Medical College and published in the Journal of Clinical Investigation and the journal Blood.

24 Nov 2010

Amorfix introduces high affinity antibodies against cancer primary cells

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that together with its partner Epitomics, high affinity antibodies to prion protein disease specific epitopes (DSEs) have been produced, which bind preferentially to several cancer primary cells and tumor cell lines, but not normal cells.

24 Nov 2010

iPrEx oral PrEP study achieves major milestone in HIV prevention research

This is a great day in the fight against AIDS. The positive results of the iPrEx oral PrEP study are a major milestone in HIV prevention research and provide important information about how antiretroviral drugs might be used for prevention by HIV-negative people at high risk for HIV infection, said AVAC Executive Director Mitchell Warren.

24 Nov 2010

Lifestyle-related diseases will be costly down the road; Americans rate their healthcare highly

Increased efforts to prevent several lifestyle-related diseases could save the United States billions of dollars a year in medical costs, according to a study scheduled to run in the American Journal of Public Health.

24 Nov 2010

IDSI submits Premarket Notification for CTLM breast imaging device to FDA

Imaging Diagnostic Systems, Inc., a pioneer in laser breast imaging, announced today that a Premarket Notification 510(k) was submitted on Monday, November 22, 2010, to the United States Food and Drug Administration (FDA). With this submission, the company moves forward in the process of seeking marketing clearance for its innovative breast imaging device, the CTLM system.

23 Nov 2010

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults. If approved, this would be the second product that contains a complete HIV treatment regimen in a single once-daily tablet.

23 Nov 2010

FDA clears BG Medicine's Galectin-3 test to identify high risk patients with cardiovascular disease

BG Medicine, Inc., a U.S.-based life sciences company, announced today that the U.S. Food and Drug Administration has cleared the company's Galectin-3 test for use in conjunction with clinical evaluation as an aid to assess the prognosis of patients diagnosed with chronic heart failure. This marks the first time the FDA has cleared a test to measure galectin-3 blood levels, and is the first novel cardiac test cleared by the FDA in five years.

23 Nov 2010

Implanted devices to treat cardiac dysfunction show success in real world use

Implanted devices that treat cardiac dysfunction in heart failure patients are as successful in "real world" use as they are in controlled clinical trial settings, according to a large new study reported in Circulation: Journal of the American Heart Association.

23 Nov 2010

Blood News and Research

Early urinary protein content test during pregnancy predicts later pre-eclampsia

FTC/TDF tablet reduces HIV infection among high-risk individuals: iPrEx study

SIRS-Lab, Pfizer collaborate to improve patients’ outcome with sepsis

Novel sharps disposal device reduces container-associated sharps injuries by 81%

Important queries about PrEP, iPrEx trial for HIV infection

HIV treatment drugs also help prevent HIV infection in high-risk men: Study

Los Angeles philanthropist foundation model to commercialize research at Ben-Gurion University

Plant-derived bioscavenger protects against pesticide and nerve agent organophosphate poisoning

Testing less frequently not a good way to economize for people living with diabetes

NIH expands genetic and clinical research database to provide access to digital study images

Software that simulates blood flow receives George Bell Prize for world's fastest supercomputing application

Centenary Institute launches new BD LSR-9 Flow Cytometer with nine lasers for studies of rare cells

Hepcidin hormone may be potential therapeutic tool for anemic blood disorders

Amorfix introduces high affinity antibodies against cancer primary cells

iPrEx oral PrEP study achieves major milestone in HIV prevention research

Lifestyle-related diseases will be costly down the road; Americans rate their healthcare highly

IDSI submits Premarket Notification for CTLM breast imaging device to FDA

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

FDA clears BG Medicine's Galectin-3 test to identify high risk patients with cardiovascular disease

Implanted devices to treat cardiac dysfunction show success in real world use

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News